Amgen Management
Management criteria checks 3/4
Amgen's CEO is Bob Bradway, appointed in May 2010, has a tenure of 14.58 years. total yearly compensation is $22.64M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 0.099% of the company’s shares, worth $140.24M. The average tenure of the management team and the board of directors is 4.9 years and 8 years respectively.
Key information
Bob Bradway
Chief executive officer
US$22.6m
Total compensation
| CEO salary percentage | 7.9% |
| CEO tenure | 14.6yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.9yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.38
Dec 14
Amgen: MariTide Underwhelms, But There Are Ways To Win
Nov 26Here's Why Amgen (NASDAQ:AMGN) Has A Meaningful Debt Burden
Nov 26Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$8b |
| Jun 30 2019 | n/a | n/a | US$8b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$19m | US$2m | US$8b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$17m | US$2m | US$2b |
Compensation vs Market: Bob's total compensation ($USD22.64M) is above average for companies of similar size in the US market ($USD12.88M).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Bradway (61 yo)
14.6yrs
Tenure
US$22,643,650
Compensation
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.6yrs | US$22.64m | 0.099% $ 140.2m | |
| Executive VP & CFO | 4.9yrs | US$7.57m | 0.0046% $ 6.5m | |
| Executive Vice President of Operations | 8.4yrs | US$7.21m | 0.011% $ 16.2m | |
| Executive VP & CTO | less than a year | US$7.90m | 0.0094% $ 13.3m | |
| Executive Vice President of Global Commercial Operations | 6.3yrs | US$8.24m | 0.0075% $ 10.6m | |
| Chief Accounting Officer & VP of Finance | 1.3yrs | no data | 0.00062% $ 877.8k | |
| Senior VP & Chief Information Officer | less than a year | no data | no data | |
| Senior VP of Research & Chief Scientific Officer | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 9.4yrs | US$7.24m | 0.0036% $ 5.0m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 4.9yrs | no data | 0.0013% $ 1.9m | |
| Senior Vice President of Global Marketing & Access | less than a year | no data | no data |
4.9yrs
Average Tenure
59yo
Average Age
Experienced Management: AMGN's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 13.2yrs | US$22.64m | 0.099% $ 140.2m | |
| Lead Independent Director | 12yrs | US$419.92k | 0.0013% $ 1.9m | |
| Co-Chair of Scientific Advisory Board | no data | US$292.01k | no data | |
| Co-Chair of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.4yrs | US$359.92k | 0.000080% $ 113.3k | |
| Independent Director | 7.8yrs | US$369.92k | 0.00023% $ 325.6k | |
| Independent Director | 11.2yrs | US$379.92k | 0.0023% $ 3.3m | |
| Independent Director | 8.2yrs | US$360.29k | 0.000080% $ 113.3k | |
| Independent Director | 6.6yrs | US$359.92k | 0.00015% $ 212.4k | |
| Independent Director | 12.6yrs | US$339.92k | 0.00051% $ 722.0k | |
| Independent Director | 7yrs | US$359.92k | 0.0012% $ 1.7m | |
| Member of Scientific Advisory Board of Cardiovascular & Metabolic | less than a year | US$360.86k | 0.0012% $ 1.6m |
8.0yrs
Average Tenure
68.5yo
Average Age
Experienced Board: AMGN's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amgen Inc. is covered by 66 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |